{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "Dealbook", "byline": {"original": "By DAVID GELLES and KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "David", "organization": "", "lastname": "GELLES"}, {"rank": 2, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "In its offer to buy Hospira, Pfizer is paying richly for what it believes will be a lucrative source of future revenue, drugs known as biosimilars.", "type_of_material": "Blog", "word_count": "1218", "lead_paragraph": null, "pub_date": "2015-02-05T07:24:35Z", "document_type": "blogpost", "slideshow_credits": null, "headline": {"main": "Pfizer Bets $15 Billion on New Class of Generic Drugs", "print_headline": "Pfizer Bets $15 Billion on New Sort of Generics", "kicker": "DealBook"}, "snippet": "In its offer to buy Hospira, Pfizer is paying richly for what it believes will be a lucrative source of future revenue, drugs known as biosimilars.", "multimedia": [{"height": 126, "url": "images/2015/02/06/business/06DRUG/06DRUG-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/02/06/business/06DRUG/06DRUG-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 415, "url": "images/2015/02/06/business/06DRUG/06DRUG-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "415", "xlarge": "images/2015/02/06/business/06DRUG/06DRUG-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/02/06/business/06DRUG/06DRUG-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/02/06/business/06DRUG/06DRUG-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://dealbook.nytimes.com/2015/02/05/pfizer-to-buy-hospira-a-drug-maker-for-15-2-billion-in-cash/", "keywords": [{"rank": "1", "is_major": "Y", "value": "Hospira Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "54d3618c38f0d81f788a23f8", "source": "The New York Times"}